![]() ![]() Accessed March 29, 2023.MSI is new sports laptop brand in India. In the KEYNOTE-051 trial, the median duration of exposure was 2.1 months.įDA converts to full approval indication for KEYTRUDA ® (pembrolizumab) for certain adult and pediatric patients with advanced microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors. The median duration of exposure in the KEYNOTE-158 and KEYNOTE-164 trials was 6.2 months. For patients who did not have CRC (n = 380), the ORR was 33% (95% CI, 28%-38%), and the DOR was 1.9 months to 63.9+ months. ![]() Of note, in patients with MSI-H/dMMR colorectal cancer (CRC n = 124), the ORR was 34% (95% CI, 26%-43%), and the duration of response (DOR) ranged from 4.4 months to 58.5+ months. The median duration of response was 63.2 months. In 168 patients who were responders, 77% of patients had a lasting response of 12 months or more, with 39% having responses that lasted 36 months or more. In a pooled analysis done with all 3 trials, the objective response rate (ORR) was 33.3% (95% CI, 29.2%-37.6%), including a complete response rate of 10.3%, and a partial response rate of 23.0%. In the trials, adults patients received 200 mg of pembrolizumab intravenously every 3 weeks, and pediatric patients received 2 mg/kg of the agent every 3 weeks until unacceptable toxicity, disease progression, or up to 24 months of treatment. “These data also further underscore the need for biomarker testing to identify patients who may be eligible for this therapy.” Diaz, Jr., MD, head of the Division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center, said in the press release. ![]() “This approval reinforces the important role of in certain patients with MSI-H or dMMR solid tumors facing a variety of cancers,” Luis A. These trials collectively analyzed 504 patients across more than 30 different types of cancer. ![]() Use of an FDA-approved test can determine if patients are eligible for treatment. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |